• Tue news: Pfizer explores sale of hospital drugs unit. FDA declines full approval of Ocaliva. AZ better than expected Q3 results. Pfizer, Lilly telehealth platforms draw scrutiny. 23andMe cutting lays off 40%. See more on our front page

[podcast]Brukinsa approval raises BeiGene’s hematology profile

Quote
cafead

cafead

Administrator
Staff member
  • cafead   Mar 20, 2024 at 09:52: PM
via BeiGene’s chief medical officer for hematology, Dr. Mehrdad Mobasher, tells Jack O’Brien about BTK inhibitor Brukinsa’s latest lymphoma approval from the FDA and offers messaging advice to medical marketers.

article source
 




Top Bottom
Back
Quote